FCCC LOGO Faculty Publications
Jordan VC
In postmenopausal women with breast cancer, switching to exemestane increased disease-free survival compared to continuing tamoxifen
Evidence-based Obstetrics and Gynecology. 2005 ;7(2) :103-104
Back to previous list
Abstract
Notes
1361259X (ISSN) Cited By: 0; Export Date: 25 May 2006; Source: Scopus CODEN: EOGVA; DOI: 10.1016/j.ebobgyn.2005.01.009 Language of Original Document: English Correspondence Address: Jordan, V.C.; Fox Chase Cancer Center Philadelphia, PA, United States Chemicals/CAS: exemestane, 107868-30-4; tamoxifen, 10540-29-1 References: Jordan, V.C., Tamoxifen: A most unlikely pioneering medicine (2003) Nature Reviews Drug Discovery, 2, pp. 205-213; Tamoxifen for early breast cancer: An overview of the randomised trials (1998) Lancet, 354, pp. 1451-1467, Early Breast Cancer Trialists' Collaborative Group; Fisher, B., Costantino, J.P., Redmond, C.K., Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 (1994) J. Natl. Cancer Inst., 86, pp. 527-537; Goss, P., Strasser, K., Aromatase inhibitors in the treatment and prevention of breast cancer (2001) J. Clin. Oncol., 19, pp. 881-894; Anastrozole alone or in combinationwith tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial (2002) Lancet, 359, pp. 2134-2139, ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trialists' Group; Goss, P.E., Ingle, J.N., Marino, S., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer (2003) N. Engl. J. Med., 349, pp. 1-10.